Brought to you by 
Janssen Pharmaceuticals gets rights to Shionogi's BACE inhibitors for Alzheimer's disease
27 Apr 2018
Executive Summary
Johnson & Johnson’s Janssen Pharmaceuticals Inc. has licensed exclusive rights to Shionogi & Co. Ltd.’s oral preclinical beta secretase (BACE) inhibitors for Alzheimer’s disease.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com